NCT07678775

Open-Label Extension Study of BBP-418 (Ribitol) for LGMD2I/R9

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2026-06-05Est. Completion: 2030-10

Enrollment target: 107 participants

Locations

Arkansas Children's Hospital, Little Rock, Arkansas, United States
University of California Irvine Medical Center, Orange, California, United States
University of Colorado Hospital (UCH) - Anschutz Medical Campus, Aurora, Colorado, United States
University of Florida Health Center for Pediatric Neuromuscular and Rare Diseases, Gainesville, Florida, United States
University of Iowa Stead Family Children's Hospital, Iowa City, Iowa, United States
University of Kansas Medical Center (KUMC), Kansas City, Kansas, United States
Kennedy Krieger Institute, Baltimore, Maryland, United States
University of Minnesota Medical School, Minneapolis, Minnesota, United States
Washington University School of Medicine, St Louis, Missouri, United States
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Children's Hospital of the Kings Daughters, Norfolk, Virginia, United States
Royal Brisbane and Women's Hospital, Brisbane, Australia
Rigshospitalet, Neuromuscular Clinic and Research Unit, Copenhagen, Denmark

LGMD2I

BBP-418 is being developed for the treatment of patients with Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I). This is a…

Richmond, United StatesEst. completion Nov 1, 2026

Limb Girdle Muscular DystrophyLimb-Girdle Muscular Dystrophy Type 2LGMD2IMuscular DystrophyLGMD2LGMDFKRPFKRP MutationFukutin Related Protein

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.